Quick Answer
Inmune Bio, Inc. reported Stockholders Equity of $23.52 million for the year ending 2025.
- Inmune Bio, Inc. showed a decrease of -26.7% in Stockholders Equity from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $18.63 million | Q2 2018: $18.03 million | Q3 2018: $17.47 million | Q1 2019: $22.86 million | Q2 2019: $26.84 million | Q3 2019: $24.71 million | Q1 2020: $22.41 million | Q2 2020: $21.68 million | Q3 2020: $41.21 million | Q1 2021: $63.56 million | Q2 2021: $43.23 million | Q3 2021: $88.26 million | Q1 2022: $75.64 million | Q2 2022: $69.93 million | Q3 2022: $63.71 million | Q1 2023: $55.30 million | Q2 2023: $50.65 million | Q3 2023: $43.93 million | Q1 2024: $28.22 million | Q2 2024: $36.28 million | Q3 2024: $38.68 million | Q1 2025: $29.67 million | Q2 2025: $28.87 million | Q3 2025: $25.38 million.
- Over the full 10 years of available data (2016 to 2025), Inmune Bio, Inc.'s Stockholders Equity has grown by 15,866.4%.
- Historical annual values: Fiscal year 2025: $23.52 million | Fiscal year 2024: $32.10 million | Fiscal year 2023: $37.34 million | Fiscal year 2022: $60.10 million | Fiscal year 2021: $80.23 million | Fiscal year 2020: $38.75 million | Fiscal year 2019: $23.61 million | Fiscal year 2018: $16.54 million | Fiscal year 2017: $18.10 million | Fiscal year 2016: -$149.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: